Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cost-effectiveness of screening and extended anticoagulation for carriers of both factor V Leiden and prothrombin G20210A.

QJM : monthly journal of the Association of Physicians - 1 Jul 2001

Marchetti M, Quaglini S, Barosi G

Abstract excerpt

Carriers of a double thrombophilic mutation (factor V Leiden and prothrombin G20210A) are at high risk of a recurrent venous thromboembolism (VTE), and may benefit from a longer course of secondary prophylaxis. We examined the costs and health benefits of screening for both the mutations, provided that double heterozygotes undergo 2 years of anticoagulation as compared to the standard 6 months. We thus pooled the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anticoagulants
Share to Confidence Intervals

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cost-Benefit Analysis

Share to Factor V

Share to Markov Chains

Share to Prothrombin

Share to Quality-Adjusted Life Years

Share to Thromboembolism

Source

Identifiers

PMID: 11435632
DOI: 10.1093/qjmed/94.7.365

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cost-effectiveness of screening and extended anticoagulation for carriers of both factor V Leiden and prothrombin G20210A.PMID 11435632Read ↗

Extended anticoagulation for prevention of recurrent venous thromboembolism in carriers of factor V Leiden--cost-effectiveness analysis.Semantic proximity Read ↗

Testing for factor V Leiden in patients with pulmonary or venous thromboembolism: a cost-effectiveness analysis.Semantic proximity Read ↗

Anticoagulation duration in heterozygous factor V Leiden: a decision analysis.Semantic proximity Read ↗

Recommendations from the EGAPP Working Group: routine testing for Factor V Leiden (R506Q) and prothrombin (20210G>A) mutations in adults with a history of idiopathic venous thromboembolism and their adult family members.Semantic proximity Read ↗

Outcome of Patients with Venous Thromboembolism and Factor V Leiden or Prothrombin 20210 Carrier Mutations During the Course of Anticoagulation.Semantic proximity Read ↗

Decision analysis model of prolonged oral anticoagulant treatment in factor V Leiden carriers with first episode of deep vein thrombosis.Semantic proximity Read ↗

Do Factor V Leiden and Prothrombin G20210A Mutations Predict Recurrent Venous Thromboembolism in Older Patients?Semantic proximity Read ↗

The risk of recurrent venous thromboembolism among heterozygous carriers of the G20210A prothrombin gene mutation.Semantic proximity Read ↗

Predictive value of factor V Leiden and prothrombin G20210A in adults with venous thromboembolism and in family members of those with a mutation: a systematic review.Semantic proximity Read ↗

The Association of Prothrombin Gene G20210A Mutation with Recurrent Venous Thromboembolism: Evidence from a Meta-Analysis.Semantic proximity Read ↗

Risk of recurrent venous thrombosis in homozygous carriers and double heterozygous carriers of factor V Leiden and prothrombin G20210A.Semantic proximity Read ↗

Influence of thrombophilia on risk of recurrent venous thromboembolism while on warfarin: results from a randomized trial.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.